ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
New prescribing guidance has been issued by the FDA for immediate-release and extended-release/long-acting opioids for pain management. The agency also announced multiple label updates, which include changes to the Boxed Warnings.
The April 29 meeting included 13 CPC members, representatives from the ACR Board of Directors and the chairs of the ACR Committee on Rheumatologic Care and its Insurance Subcommittee. The group is part of an expanded effort to ensure the ACR is meeting the needs of rheumatologists in independent practice.
After significant pushback from the AMA, ACR and other medical societies, Cigna has delayed implementation of changes to its modifier 25 reimbursement policy, originally scheduled to take effect May 25.
Scientific publishing requires a commitment to clear writing, concise narratives and a willingness to accept feedback. Daniel Solomon, MD, editor-in-chief of Arthritis & Rheumatology, provides insights into his experiences.
Access to care is critical for treating arthritis and other chronic rheumatic conditions. That’s why choosing the best Medicare plan fit is such an important decision. Use these tips from the Arthritis Foundation’s Nick Turkas, MS, to help your patients make their best choice for insurance coverage.
Past studies have suggested that patients with rheumatoid arthritis (RA) who consume a moderate amount of alcohol may experience lower disease activity and higher quality of life than non-drinkers. In this study, Alfredsson, et al. confirmed earlier studies’ claims that alcohol consumption reduces disease activity in a dose-dependent manner, and also indicated that patients who stopped drinking post-baseline experienced worsened disease activity, more pain and a lower quality of life.
The ACR will co-lead with the American Society of Clinical Oncology a resolution on in-office dispensing of specialty drugs and will lead 10 other specialty societies to advance a resolution on the proposed NIH Public Access Plan and equitable access to quality clinical research.
The public health emergency (PHE), in place since 2020, officially expired at midnight on May 11. The PHE declaration allowed significant flexibility in the healthcare system. The end of the PHE impacts several policies, including changes in Medicare and Medicaid policies. What do these changes mean for providers?
This legislative season has seen key pharmacy benefit manager reforms but slow movement on other issues, such as copay accumulators and utilization management. The ACR is also monitoring emerging topics, such as biomarker testing and post-public health emergency telehealth reforms.